Compare Gilead Sciences, Inc. (GILD) vs KB Financial Group, Inc. (KB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs KB Financial Group, Inc. — how do they compare? Gilead Sciences, Inc. trades at $136.3 (market cap $163.51B), while KB Financial Group, Inc. trades at $120.81 (market cap $41.90B). The key difference: Gilead Sciences, Inc. is far larger — about 3.9× KB Financial Group, Inc.'s market cap, and KB Financial Group, Inc. pays the higher dividend (2.58%). Which is the better fit depends on your goals.
| GILD | KB | |
|---|---|---|
Market Cap | $163.51B | $41.90B |
Sector | Health | Financials |
52-Week High | $155.80 | $123.25 |
52-Week Low | $108.22 | $77.50 |
Enterprise Value | $178.05B | — |
Dividend Yield | 2.49% | 2.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
KB Financial Group (KB) trades at $121.85, up 0.94% with strong technical momentum as moving averages signal bullish conditions. The company demonstrates robust fundamentals with revenue growth from $21.23T in 2025 to $21.67T projected for 2026, net income margin expanding to 27.82%, and consistent earnings beats in recent quarters. Recent news highlights aggressive non-banking diversification and potential dividend increases.
The outlook remains positive with valuation metrics appearing reasonable (P/E 11.69, P/B 1.12) and analyst consensus leaning bullish despite mixed ratings. Key risks include execution of diversification strategy and market volatility, while institutional sentiment is supported by ROE expansion potential and strong cash flow generation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About KB Financial Group, Inc.
KB Financial is the parent company of KB Kookmin Bank, Korea's largest commercial bank, with a 13.1% share of loans as of 2021. Its predecessor banks were established in the 1960s as government policy banks and privatized in the 1990s. Its credit card subsidiary KB Kookmin Card is the number-three player behind Shinhan Card and Samsung Card. KB has in recent years expanded its nonbank business by buying LIG Insurance and Hyundai Securities, making KB a top-five player in nonlife insurance and in securities, and most recently by buying Prudential Life Insurance Korea. It also has KB Capital, which provides leasing and installment finance.
Read more on KB →
